Literature DB >> 19454465

Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

E Van Cutsem1, J Oliveira.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19454465     DOI： 10.1093/annonc/mdp130

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  57 in total

1.  The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1R-Independent Inhibition of CCR2 Signaling and Monocyte Recruitment.

Authors:  Daniel P Regan; Jonathan W Coy; Kirti Kandhwal Chahal; Lyndah Chow; Jade N Kurihara; Amanda M Guth; Irina Kufareva; Steven W Dow
Journal:  J Immunol       Date:  2019-04-10       Impact factor: 5.422

2.  Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date.

Authors:  Guoliang Zhang; Xile Zhou; Caizhao Lin
Journal:  Int J Clin Exp Med       Date:  2015-01-15

Review 3.  Sequencing of treatment in metastatic colorectal cancer: where to fit the target.

Authors:  Sally Temraz; Deborah Mukherji; Ali Shamseddine
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

4.  Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti-EGFR therapies.

Authors:  Johann Dréanic; Marianne Maillet; Marion Dhooge; Olivier Mir; Catherine Brezault; François Goldwasser; Stanislas Chaussade; Romain Coriat
Journal:  Med Oncol       Date:  2013-07-10       Impact factor: 3.064

5.  Acriflavine enhances the antitumor activity of the chemotherapeutic drug 5-fluorouracil in colorectal cancer cells.

Authors:  Parisa Zargar; Esmaeel Ghani; Farideh Jalali Mashayekhi; Amin Ramezani; Ebrahim Eftekhar
Journal:  Oncol Lett       Date:  2018-04-25       Impact factor: 2.967

6.  Scutellaria barbata D. Don inhibits migration and invasion of colorectal cancer cells via suppression of PI3K/AKT and TGF-β/Smad signaling pathways.

Authors:  Yiyi Jin; Wujin Chen; Hong Yang; Zhaokun Yan; Zijun Lai; Jianyu Feng; Jun Peng; Jiumao Lin
Journal:  Exp Ther Med       Date:  2017-10-02       Impact factor: 2.447

7.  A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.

Authors:  Mohamad Bassam Sonbol; Raed Benkhadra; Zhen Wang; Belal Firwana; Daniel J Walden; Kabir Mody; Joleen M Hubbard; M Hassan Murad; Daniel H Ahn; Tanios Bekaii-Saab
Journal:  Oncologist       Date:  2019-06-04

8.  Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer.

Authors:  P García-Alfonso; A J Muñoz-Martin; S Alvarez-Suarez; Y Jerez-Gilarranz; M Riesco-Martinez; P Khosravi; M Martin
Journal:  Br J Cancer       Date:  2010-10-26       Impact factor: 7.640

9.  A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients.

Authors:  Kuniaki Aridome; Shin-Ichirou Mori; Kenji Baba; Masayuki Yanagi; Masahiro Hamanoue; Futoshi Miyazono; Kouki Tokuda; Hiroshi Imamura; Yoshito Ogura; Kouichi Kaneko; Fumio Kijima; Kousei Maemura; Sumiya Ishigami; Shoji Natsugoe
Journal:  Mol Clin Oncol       Date:  2015-12-31

10.  The role of p53 in combination radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer.

Authors:  Yunjun Guo; Jesse J Parry; Richard Laforest; Buck E Rogers; Carolyn J Anderson
Journal:  J Nucl Med       Date:  2013-07-19       Impact factor: 10.057
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.